Thursday, July 9, 2026

Patent intelligence · US

US 10052371

Compositions and methods for treatment of cancer using bacteria

granted A61KA61K2039/521A61K2039/522A61K2039/523
Status granted
Linked drugs 1
Pipeline programs 6
Years to expiry 12
Applicant portfolio 6
Patent details — US 10052371
Jurisdiction
US
Status
granted
Grant date
Aug 21, 2018
Expiration
Aug 16, 2038
Claims
12
CPC classes
A61K, A61K2039/521, A61K2039/522, A61K2039/523
View on Google Patents ↗

Quick answer

US 10052371 (Compositions and methods for treatment of cancer using bacteria) is held by Decoy Biosystems, Inc.. Status: granted. Granted Aug 21, 2018. Expires Aug 16, 2038 (12 years remaining) — relevant for patent-cliff and LOE planning.

Key facts

Grant date
Expiration
Claims
12
CPC classes
A61K, A61K2039/521, A61K2039/522, A61K2039/523, A61K2039/585, A61K31/11

More from Decoy Biosystems, Inc.

Related pharmaceutical patents in our USPTO index.

  1. US 12226474

    Methods and compositions for treating infections

    Decoy Therapeutics Inc. · Expires Feb 13, 2045

    granted
  2. US 11147844

    Methods of treatment of infections using bacteria

    Decoy Biosystems, Inc. · Expires Oct 14, 2041

    granted
  3. US 11045504

    Compositions and methods for treatment of cancer using bacteria

    Decoy Biosystems, Inc. · Expires Jun 24, 2041

    granted
  4. US 10195259

    Compositions and methods for treatment of cancer using bacteria

    Decoy Biosystems, Inc. · Expires Jan 31, 2039

    granted
  5. US 9265804

    Compositions and methods for treatment of cancer using bacteria

    Decoy Biosystems, Inc. · Expires Feb 18, 2036

    granted

Frequently asked questions

What is US patent 10052371?

US 10052371 (Compositions and methods for treatment of cancer using bacteria) is held by Decoy Biosystems, Inc.. Status: granted. Granted Aug 21, 2018. Expires Aug 16, 2038 (12 years remaining) — relevant for patent-cliff and LOE planning.

Who owns US 10052371?

Decoy Biosystems, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 6 pharmaceutical patents for this assignee.

When does US 10052371 expire?

Our index shows an expiration date of Aug 16, 2038 (12 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.